Abstract: RNA-seq has matured into a vital tool for studying RNA biology. This study compared two RNA-seq platforms (MGI DNBSEQ and Illumina NextSeq 500) and two microarray platforms (GeneChip Human Transcriptome Array 2.0 and Illumina Expression BeadChip) in healthy individuals administered recombinant human erythropoietin (rHuEPO). The objective was to achieve transcriptome-wide quantification of differential gene expression. Results demonstrate that total RNA DNB-seq generated a significantly higher number of target genes compared to other platforms. Pathway enrichment analyses revealed that these genes correlate not only to erythropoiesis and oxygen transport but also to tissue protection and immune regulation. This research establishes a comprehensive knowledge base of genes relevant to EPO biology through rigorous cross-platform validation.
Introduction
Erythropoietin (EPO) is a primary hormone regulating red blood cell production. While its clinical use for treating anemia is well-established, its use as a performance-enhancing drug in sports necessitates sophisticated detection methods. Furthermore, the full scope of EPO's biological influence—particularly its non-erythropoietic effects on the immune system and tissue protection—remains partially understood. This study addresses these gaps by performing a head-to-head comparison of four modern transcriptomic technologies to map the human response to rHuEPO administration.
Methodology
The study involved 18 endurance-trained Caucasian males who received rHuEPO over several weeks. Blood samples were collected at eight time points (baseline, during treatment, and post-treatment). These samples were analyzed using four distinct platforms:
- MGI DNBSEQ-G400RS: Total RNA-sequencing.
- Illumina NextSeq 500: mRNA-sequencing.
- GeneChip HTA 2.0: Microarray.
- Illumina HumanHT-12 v4: Microarray.
A data triangulation approach was employed to identify biological signals that persisted across technologies, validated through Gene Set Enrichment Analysis (GSEA) and Reactome pathway analysis.
Results and Discussion
Superiority of Total RNA-Sequencing
The comparison revealed a stark difference in platform sensitivity. The MGI DNBSEQ platform, which sequences total RNA (including transcripts without poly-A tails), identified 1,552 differentially expressed genes (DEGs). In contrast, the Illumina mRNA-seq platform identified only 582 DEGs, and the microarray platforms were even less sensitive. At the peak response period (EPO4), approximately 66.8% of the genes identified were unique to the MGI platform.
Biological Insights: Beyond Erythropoiesis
The high sensitivity of the MGI platform allowed for the discovery of EPO’s roles in immune regulation and metabolic signaling. The data showed significant impacts on MHC class II antigen presentation and T-cell regulation, confirming EPO's function as a complex immune modulator. Additionally, gene sets related to mitophagy and mTOR signaling were identified, suggesting that EPO assists cells in managing oxidative stress and promoting survival.
The 119-Gene Signature
Through cross-platform triangulation, the researchers identified a core signature of 119 high-confidence genes. This signature includes well-known erythropoietic targets such as ALAS2 and FECH, alongside novel immune-related targets. While RNA-seq platforms showed strong correlation (r = 0.74 to 0.85), the correlation with microarrays was significantly lower, indicating that microarrays may lack the resolution required for subtle physiological studies.
Conclusion
This study demonstrates that total RNA-sequencing (MGI DNBSEQ) provides the most comprehensive view of the transcriptomic response to rHuEPO. The identified 119-gene signature serves as a robust knowledge base for EPO biology and offers a potential framework for developing more effective anti-doping strategies, such as a transcriptomic "Biological Passport." Future research should aim to validate these findings in more diverse populations to ensure broader applicability.
Summary updated